Citation Impact
Citing Papers
Bridging the gaps in design methodologies by evolutionary optimization of the stability and proficiency of designed Kemp eliminase KE59
2012 StandoutNobel
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
2008
Targeting of Cyclic AMP Degradation to β 2 -Adrenergic Receptors by β-Arrestins
2002 StandoutScienceNobel
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
2007
Protein stability promotes evolvability
2006 StandoutNobel
PDE4 cAMP-specific phosphodiesterases
2001
Computational Stabilization of a Non‐Heme Iron Enzyme Enables Efficient Evolution of New Function
2024 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Pan-cancer patterns of somatic copy number alteration
2013
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Targeting ADAMS and ERBBs in lung cancer
2006
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
2007
Optimization of DNA shuffling for high fidelity recombination
1997
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
IDH1andIDH2Mutations in Gliomas
2009 Standout
Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation
1999 StandoutNatureNobel
Phosphorylation and Activation of a cAMP-specific Phosphodiesterase by the cAMP-dependent Protein Kinase
1996
The Molecular Biology of Cyclic Nucleotide Phosphodiesterases
1999
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Random-priming in vitro recombination: An effective tool for directed evolution
1998 StandoutNobel
Lung Cancer
2008 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
The type III epidermal growth factor receptor mutation
2001
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
2008
Nucleotide exchange and excision technology (NExT) DNA shuffling: a robust method for DNA fragmentation and directed evolution
2005
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
2017 StandoutNature
Improved properties of FLP recombinase evolved by cycling mutagenesis
1998
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
ErbBs in lung cancer
2008
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
2006
Directed evolution of enzyme catalysts
1997 StandoutNobel
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
2008
Targeted Molecular Therapy of GBM
2003
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Malignant Gliomas in Adults
2008 Standout
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
Kemp elimination catalysts by computational enzyme design
2008 StandoutNatureNobel
High efficiency family shuffling based on multi-step PCR and in vivo DNA recombination in yeast: statistical and functional analysis of a combinatorial library between human cytochrome P450 1A1 and 1A2
2000
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Where next for gefitinib in patients with lung cancer?
2006
β2-Adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics
2007 StandoutNobel
[26] Methods for in vitro DNA recombination and random chimeragenesis
2000 StandoutNobel
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor
2001
Cold Adaptation of a Mesophilic Subtilisin-like Protease by Laboratory Evolution
2000 StandoutNobel
Integration of EGFR inhibitors with radiochemotherapy
2006
Phosphoinositides in cell regulation and membrane dynamics
2006 StandoutNature
The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
2009
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
2007
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
2008
Discovery and saturation analysis of cancer genes across 21 tumour types
2014 StandoutNature
Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
2007
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Oncogenic PI3K deregulates transcription and translation
2005
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
2012
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
2007
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
2006
Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas
2006
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
Computational method to reduce the search space for directed protein evolution
2001 StandoutNobel
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
2006
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
In the light of directed evolution: Pathways of adaptive protein evolution
2009 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
2011
KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
2007
Directed evolution of a thermostable esterase
1998 StandoutNobel
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
2008
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
Phosphodiesterase 4D is required for β 2 adrenoceptor subtype-specific signaling in cardiac myocytes
2005 StandoutNobel
A structural view of evolutionary divergence
1999 StandoutNobel
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
2017
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
2006
Functional and nonfunctional mutations distinguished by random recombination of homologous genes
1997 StandoutNobel
Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines
2006
Library Generation by Gene Shuffling
2014
Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells BearingEGFRGene Mutation and Amplification
2007
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
2007
Enzyme engineering reaches the boiling point
1998 StandoutNobel
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
2007
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
2005
Works of Ian Lorimer being referenced
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
2005
Random recombination of antibody single chain Fv sequences after fragmentation with DNasel in the presence of Mn2+
1995
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.
1999
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
2013
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
1996
Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21
2005
Protein kinase A regulation of cAMP phosphodiesterase expression in rat skeletal myoblasts.
1994
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
1995